Pharsight

1. List of Incivek drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7820671	VERTEX PHARMS	Peptidomimetic protease inhibitors	Feb, 2025 (2 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8431615	VERTEX PHARMS	Dose forms	May, 2028 (5 years from now)

Drugs and Companies using TELAPREVIR ingredient

Market Authorisation Date: 23 May, 2011

Treatment: Method of treating chronic hepatitis c

Dosage: TABLET;ORAL

Strength	Dosage	Availability
375MG	TABLET;ORAL	Discontinued

2. List of Kalydeco drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224	VERTEX PHARMS	Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide	Dec, 2026 (3 years from now)
US7495103	VERTEX PHARMS	Modulators of ATP-binding cassette transporters	May, 2027 (4 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162	VERTEX PHARMS	Modulators of ATP-binding cassette transporters	Jun, 2025 (2 years from now)
US8354427	VERTEX PHARMS	Modulators of ATP-binding cassette transporters	Jul, 2026 (3 years from now)
US8410274	VERTEX PHARMS	Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide	Dec, 2026 (3 years from now)
US9670163	VERTEX PHARMS	Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide	Dec, 2026 (3 years from now)
US8324242	VERTEX PHARMS	Modulators of ATP-binding cassette transporters	Aug, 2027 (4 years from now)
US10646481	VERTEX PHARMS	Pharmaceutical composition and administrations thereof	Aug, 2029 (6 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 21, 2027

Drugs and Companies using IVACAFTOR ingredient

Market Authorisation Date: 31 January, 2012

Treatment: Use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; Method of treating cystic fibrosis; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

Dosage: TABLET;ORAL